Ron DePinho: CRISPR Progress in Cellular Immunotherapy
Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on LinkedIn about a recent article by Heidi Ledford, adding:
”CRISPR progress in cellular immunotherapy …
Researchers used a combination of engineered viruses and virus-like particles to target T cells. The particles carried RNA and protein machinery needed for CRISPR–Cas9 gene editing, and the viruses contained the DNA encoding the CAR protein. T cells had to receive both payloads to become a CAR T cell.
In mice with leukaemia and multiple myeloma, tumors were completely wiped out in the treated mice, and more than half of the treated group with sarcomas entered full remission. A biotechnology company, Azalea Therapeutics is now testing the approach in monkeys and hopes to have clinical trials in people by the end of next year. While encouraging, it remains to be seen how long the effects of the treatment last, or whether CRISPR–Cas9 might be introducing any unwanted changes to the genome.”
Title: CRISPR makes enhanced cancer-fighting immune cells inside mice
Author: Heidi Ledford
Read the Full Article on Nature

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C